Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731697 | 1.00 | CA2 (0.51) | CA2NQO2SLC7A5CA1POLB | |
| SCHEMBL731698 | 1.00 | CA2 (0.51) | CA2NQO2SLC7A5CA1POLB | |
| SCHEMBL5264017 | 0.87 | GLS (0.51) | SLC7A5NAMPTCTSKCTSSCTSB | |
| SCHEMBL5261267 | 0.87 | GLS (0.51) | SLC7A5NAMPTCTSKCTSSCTSB | |
| SCHEMBL3933847 | 0.85 | CA2 (0.48) | CA2NQO2POLBNAMPTIDO1 | |
| SCHEMBL27832827 | 0.85 | NQO2 (0.51) | CA2NQO2CA1POLBNAMPT | |
| SCHEMBL693223 | 0.84 | SIGMAR1 (0.53) | CA2NAMPTIDO1CTSKCTSS | |
| SCHEMBL9985225 | 0.84 | NQO2 (0.52) | CA2NQO2CA1POLBNAMPT | |
| SCHEMBL6414458 | 0.83 | CA2 (0.49) | CA2NQO2CA1POLBNAMPT | |
| SCHEMBL1718277 | 0.83 | NQO2 (0.51) | CA2NQO2CA1POLBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | CA2 2117/4885NQO2 4056/4885SLC7A5 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.